| First author [ref.] | Marker | Trial | Patients n | Overall survival | External validation |
| Kamal [41] | MSH2 | IALT (stage I–III) | 768 | HR 0.66, p=0.01: High expression: prognostic and predictive for overall survival in adjuvant arm versus observation | No |
| Olaussen [25] | ERCC1 | IALT (stage I–III) | 761 | HR 0.66, p=0.009: High expression: prognostic and predictive for overall survival in adjuvant arm versus observation | No for predictive value: failure of LACE-Bio validation [44] |
| Filipits [55] | MRP2 | IALT (Stage I–III) | 782 | HR 1.37, p=0.07: High expression: worse prognosis | No |
| Sève [60] | β-tubulin3 | JBR10 (stage I–III) | 256 | HR 1.72; p=0.04: High expression: worse prognosis | No for predictive value in LACE-Bio Yes for prognosis value in LACE-Bio [65] |
| de Fraipont [35] | RASSF1A methylation | IFCT-0002 (stage I–II) | 208 | Adjusted HR 2.13, p=0.0013: Prognostic and predictive for PFS: gemcitabine versus paclitaxel | No Bootstrap internal validation for prognosis |
| Levallet [26] | β-tubulin3 | IFCT-0002 (stage I–II) | 461 | Adjusted HR 1.69, p=0.035: High expression: prognostic but not predictive | No Bootstrap internal validation |
| Zhu [61] | 15-gene signature | JBR10 (stage I–III) | 133 | Adjusted HR 15.02, p<0.001: High-risk group of worse prognosis | Yes for prognosis value No for predictive value |
| Mascaux [62] | 3-mIR signature | IFCT-0002 (stage I–II) | 276 | Adjusted HR 0.445, p=0.0002: Signature of 3mIR: prognostic value | No Bootstrap internal validation |
| Chen [63] | 94-gene signature | Director’s Challenge Consortium (stage I–III) | 442 | Adjusted HR 2.14, p<0.01: malignancy-risk genes | Yes for prognosis value No for predictive value |
| Kratz [64] | 14-gene signature | UCSF nonsquamous series + KPDOR series (stage I–III) | 361 | HR 2.37, p<0.001: purely prognostic | Yes for prognosis |
MSH2: MutS homologue 2; MRP2: multidrug resistance-associated protein-2; IALT: International Adjuvant Lung Cancer Trial; UCSF: University of California, San Francisco (CA, USA); KPDOR: Kaiser Permanente Division of Research; HR: hazard ratio; PFS: progression free survival.